Study Comparing High-Dose Aspirin, Low-Dose Aspirin, and Prasugrel Plus Low-Dose Aspirin for Three Months After Coronary Artery Bypass Surgery in Stable Coronary Artery Disease Patients

What this Trial Is About

This research aims to compare the effects of prasugrel combined with low-dose aspirin versus high-dose aspirin alone and low-dose aspirin alone in patients with chronic coronary syndrome undergoing coronary artery bypass grafting CABG. The study is a multicenter, randomized trial focused on evaluating graft failure rates and other cardiovascular outcomes in patients with stable coronary artery disease after CABG. Participants will be randomly assigned to one of three groups prasugrel 10 mg plus low-dose aspirin 75 mg daily, high-dose aspirin 300 mg daily, or low-dose aspirin 75 mg daily. Treatments are administered orally for three months, followed by all groups receiving low-dose aspirin alone. The study monitors graft function and cardiovascular events up to 12 months and beyond. During the study, participants will undergo assessments to evaluate graft failure, ischemic and bleeding events, and quality of life at 6, 12, and 60 months after surgery. The primary outcome is the incidence of graft failure at 12 months comparing the different treatments. Participants will be monitored through clinical follow-ups and evaluations to track treatment effects and safety over time.

Comparing High and lOw-dose asPirin With Dual anTIplatelet Therapy for Three Months Using prasUgrel and aSpirin Following Coronary Artery Bypass Grafting. (OPTIMUS-CABG Trial)